TheEdgeResearch
Home / Stocks / ACBM

Acro Biomedical Co., Ltd. (ACBM)

OTC Healthcare Biotechnology
$0.03 ▲ +0.00%
Market Cap
$1.6M
Sector
Healthcare
Industry
Biotechnology
Beta
-2.31
52-Wk Range
0.0007-0.1
CEO
Yu-Ting Su
Country
US
Currency
USD

Acro Biomedical Co., Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Fishers, IN, US. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $1.6M. On trailing twelve-month figures it carries a trailing P/E of -11.30, a net margin of 0.0%. Its beta of -2.31 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-11.30
Price / Sales
0.00
Price / Book
-3.65
EV / EBITDA
-9.41
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.88
Current ratio
0.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2021-01-08
Headquarters
Fishers, IN, US
About Acro Biomedical Co., Ltd.

Acro Biomedical Co., Ltd. focuses on the development and commercialization of dietary supplements. The company offers products such as cordycepin and powdered cordyceps, which come from a type of fungus traditionally utilized in Chinese medicinal practices. Originally founded in 2014, the organization was known as Killer Waves Hawaii, Inc. until it rebranded as Acro Biomedical Co., Ltd. in January 2017. Its operations are headquartered in Fishers, Indiana.

Comparable companies

Acro Biomedical Co., Ltd. is most often compared with the following Healthcare names:

AMBSBSSPHDVYIBXGIGRWITMCMLPHNSPDFONBIRGDXQ
More research on ACBM
ACBM technical analysis ACBM TheEdge Score Compare against peers
Open full interactive analysis & DCF →